HCA Profit Warning & Insulin Pricing Shifts

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, the HCA profit warning today really crystallizes the access pressures we're seeing across the system.

MarcusSame here. We're looking at HCA's uninsured surge — what it signals for hospital sustainability and drug access. Then subQ Leqembi approval — how it changes Alzheimer's evidence generation. Next, the FTC insulin settlement — PBM practice shifts and pricing implications. And ICER's Evidence First program — early engagement with HTA bodies.

SaraThat second one is particularly interesting — the subQ formulation demands real-world evidence on adherence that wasn't needed for IV, and that's going to reshape HEOR timelines.

MarcusExactly. Let's get into it.

MarcusStarting with HCA Healthcare: they've issued a profit warning citing a 30% increase in uninsured patients and 20% rise in uncompensated care costs. This isn't just HCA — it's a bellwether for US hospital systems facing Medicaid redeterminations and economic pressures.

SaraThat 30% uninsured jump is staggering. What strikes me is the budget impact on hospitals — when uncompensated care costs surge, it creates downstream pressure on drug formularies and reimbursement decisions to offset losses.

MarcusAbsolutely. And this connects to broader access challenges: as safety nets fray, we'll see more patients falling into coverage gaps. The question is whether manufacturers will need to develop tiered pricing or patient support programs specifically for this population.

SaraThat's one read — but I'd frame it slightly differently. Payers will likely tighten formularies to manage their own budgets, meaning even insured patients might face higher cost-sharing for newer drugs. It's a double-edged sword for access.

MarcusFair point. What's interesting is how this could accelerate value-based contracting tied to hospital readmissions or adherence metrics. If hospitals bear the brunt of uncompensated care, they may push harder for outcomes-based agreements.

SaraI wonder though — with HCA being the largest for-profit chain, does this pressure lead to more consolidation in the hospital sector? And how would that affect negotiating leverage with pharma on pricing?

MarcusThat's the billion-dollar question. For now, the key takeaway is that access challenges are becoming more acute and system-wide, not just patient-specific.

MarcusSwitching to subQ Leqembi: FDA approved the subcutaneous formulation based on the same 27% cognitive decline reduction data as IV. But the convenience factor could dramatically change real-world adherence and outcomes.

SaraThe methodological challenge here is huge. We now need RWE to validate whether subQ delivers comparable real-world effectiveness — and whether improved adherence offsets potential differences in pharmacokinetics. HEOR teams will need to pivot from trial-based to real-world evidence generation.

MarcusExactly. And this isn't just about Leqembi — it's a template for biologics moving from IV to subcutaneous. The evidence bar just got higher for comparative effectiveness, especially when payers question whether the convenience premium justifies the cost.

SaraThat's fair, though I think payers would see it differently. They'll demand head-to-head trials or robust RWE showing non-inferiority before accepting the same price for a different administration route. The burden of proof shifts to manufacturers.

MarcusI agree. What's striking is how this accelerates the need for patient-reported outcomes too — convenience matters, but we need data on quality of life impacts to justify the switch.

SaraAnd from a payer perspective, the budget impact could be significant if adherence improves but the price remains high. We'll need cost-effectiveness models that incorporate adherence gains.

MarcusThis is one of those stories where the regulatory approval is just the starting point. The real HEOR work begins now.

MarcusThe FTC settlement with CVS Caremark over insulin pricing: $100 million payment and mandated PBM practice changes. Allegations included steering patients to higher-cost insulin products.

SaraThis is a watershed moment for PBM transparency. The fact that the FTC intervened signals that anti-competitive practices in insulin pricing are now a federal priority. But I'm skeptical about the $100 million penalty — it's a rounding error for CVS Caremark's revenue.

MarcusThat's a valid point. The real significance is the practice changes: if PBMs can no longer incentivize higher-cost insulin, it could lower net prices and improve access. But we need to see how this plays out in formulary design.

SaraThe part that gives me pause is the precedent. If insulin gets this scrutiny, will it extend to other high-cost chronic therapies? And what does this mean for rebate structures? Payers might push harder for pass-through rebates if PBMs can't keep them.

MarcusAbsolutely. And it connects to broader pricing debates: if PBMs are forced to act as true fiduciaries, we might see more value-based contracts tied to actual patient costs, not list prices.

SaraI'd push back slightly on that. The settlement doesn't address the root cause — the fragmented insulin market with multiple analogs. Until we have more biosimilars or price controls, the system remains inefficient.

MarcusFair. But this settlement could accelerate consolidation in the insulin space or push manufacturers toward simpler pricing models. Either way, the access landscape is shifting.

MarcusICER's new Evidence First program: early evidence generation services for sponsors to design trials with HTA endpoints from day one. This is a direct response to industry demand for earlier HTA engagement.

SaraThe strategic shift here is fascinating. Instead of waiting for Phase 3 data, sponsors can now co-design evidence packages with HTA bodies. But I wonder if this creates a new bottleneck — will ICER have the capacity to handle all these early submissions?

MarcusThat's the critical question. If they scale successfully, this could become the new standard for evidence development. But if capacity constraints emerge, we might see a two-tier system where only well-resourced sponsors can access this advantage.

SaraThat's one read — I'd frame it slightly differently. The real value is in de-risking development: if sponsors know what evidence payers need upfront, they can avoid late-stage surprises. But it requires significant HEOR resource investment early on.

MarcusExactly. And this connects to global trends — we're seeing similar early engagement models in Europe with JCA scientific advice. The question is whether this harmonizes or fragments HTA requirements.

SaraThe part that gives me pause is the timeline. If sponsors commit to HTA endpoints too early, it might limit flexibility in trial design. There's a tension between standardization and innovation here.

MarcusThat's a fair trade-off. But for complex therapies, this could reduce late-stage failures and improve the efficiency of evidence generation. We'll be watching how sponsors adopt this.

SaraA lot to think about today. I'll be watching how the FTC insulin settlement actually impacts PBM practices — whether we see meaningful formulary changes or just window dressing.

MarcusSame — and for me the thread running through today is the acceleration of real-world evidence needs. From subQ formulations to hospital access challenges, the data landscape is fundamentally shifting.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.